Biogen (BIIB) PT Lowered to $200 at Barclays
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $215.50 -1.62%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 19 | Down: 9 | New: 26
Join SI Premium – FREE
Barclays analyst Carter Gould lowered the price target on Biogen (NASDAQ: BIIB) to $200.00 (from $215.00) while maintaining a Equalweight rating.
You May Also Be Interested In
- Beijer Ref AB (BEIJB:SS) PT Raised to SEK150 at Citi
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- HubSpot Inc (HUBS) PT Raised to $290 at UBS, Stock Expected to Be Execution-Driven Near-Term
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
